SAS Output

10-APR-2021 6:10

LEUK ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1318-ALL, Age 65+, Ph±, Blinatumomab 1 T 1 Induction: Ph- 58 31 0 0 0 0 0 06/30/2015 100 42
        2 Induction: Ph+/Ph-like   26 3 1 0 0 0      
            57 3 1 0 0 0      
 
    2 Y 3 Post-remission: Ph- 58 20 0 0 0 0 0 06/30/2015    
        4 Post-remission: Ph+/Ph-like   20 5 1 1 0 0      
            40 5 1 1 0 0      
 
    3 Y 5 Maintenance: Ph- 58 14 0 0 0 0 0 06/30/2015    
        6 Maintenance: Ph+/Ph-like   17 7 2 0 0 0      
            31 7 2 0 0 0      
 
  S1712-CML, Chronic Phase, TKI +/- Ruxolitinib 1 Y 1 Single Agent TKI 84 24 10 6 2 1 0 10/24/2018 156 68
        2 TKI + Ruxolitinib   28 16 9 4 3 0      
            52 26 15 6 4 0      
 
  S1905-T-ALL/T-LBL, Rel/Ref, OBI-3424 1 Y 1 OBI-3424-8mg 64 1 1 1 1 0 0 02/08/2021 41 22
            1 1 1 1 0 0      
 
  S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O 1 Y 2 Early V-O 247 2 2 2 2 1 1 03/02/2021 154 54
            2 2 2 2 1 1      
 
Yes A041701-AML, Age 60+, Conv Chemo +/- Uproleselan 0 E Total Registrations   38 18 10 7 3 2 06/10/2019 132 63
            38 18 10 7 3 2      
 
    1 E Total Registrations   25 13 7 5 2 1 06/10/2019    
            25 13 7 5 2 1      
 
  A041702-CLL, Stg I-IV, IO with IM versus IVO 0 E Total Registrations   45 18 8 5 2 1 03/04/2019 268 121
            45 18 8 5 2 1      
 
    1 E Total Registrations   37 13 6 3 3 0 03/04/2019    
            37 13 6 3 3 0      
 
    2 E Total Registrations   17 17 12 5 1 1 03/04/2019    
            17 17 12 5 1 1      
 
  EA9161-CLL, untreated, IOV vs IO in younger pts 0 E Total Registrations   117 68 41 24 12 6 02/12/2019 260 129
            117 68 41 24 12 6      
 
    1 E Total Registrations   154 57 31 15 5 0 02/12/2019    
            154 57 31 15 5 0      
 
No A041501-B-Cell ALL, Frontline Tx +/- Intuzumab Ozo 0 E Total Registrations   49 27 12 7 1 1 11/09/2018 189 84
            49 27 12 7 1 1      
 
    1 E Total Registrations   39 23 9 6 1 1 11/09/2018    
            39 23 9 6 1 1      
 
    2 E Total Registrations   27 16 9 4 3 1 11/09/2018    
            27 16 9 4 3 1      
 
  A041703-ALL, Dx, Inotuzumab Ozogamicin + Blinatumomab 0 E Total Registrations   4 4 3 0 0 0 08/13/2020 86 48
            4 4 3 0 0 0      
 
    1 E Total Registrations   3 3 3 0 0 0 08/13/2020    
            3 3 3 0 0 0      
 
  EA9171-CML, Anti-PD-1 Pembrolizumab + TKIs 0 E Total Registrations   1 0 0 0 0 0 02/18/2020 85 38
            1 0 0 0 0 0      
 
    1 E Total Registrations   1 0 0 0 0 0 02/18/2020    
            1 0 0 0 0 0      
 
  EA9181-ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab 0 E Total Registrations   1 1 1 1 0 0 02/19/2021 8 7
            1 1 1 1 0 0      
 
    1 E Total Registrations   1 1 1 1 0 0 02/19/2021    
            1 1 1 1 0 0      
 
    2 E Total Registrations   1 1 1 1 0 0 02/19/2021    
            1 1 1 1 0 0      
 

10-APR-2021 6:10

LEUK Recently Closed Studies Accrual Report

The REPORT Procedure

Detailed and/or summarized report

Table 1

OPEN Study Date
Closed
Reg. Arm Total
Regs
Regs
Last
30 Days
Regs
Last
7 Days
T S1318-ALL, Age 65+, Ph±, Blinatumomab 15-Apr-21 1 1 Induction: Ph- 31 0 0
        2 Induction: Ph+/Ph-like 26 0 0